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Abstract
Previous studies reported controversial results concerning alterations of astrocytes in schizophrenia. Because S100B may be
regarded as a marker for astrocytes, the objective of this study was to examine S100B serum concentrations in 30 patients with
schizophrenia with a monoclonal two-site immunoluminometric assay that specifically detects S100B. An ANOVA revealed
medication ( p < 0.005) and deficit vs. nondeficit syndrome ( p < 0.05) as factors that influenced S100B significantly. S100B was
higher in schizophrenic patients treated with antipsychotic drugs for approximately 3 weeks (241.1F152.5 ng/l) in comparison
with unmedicated patients (111.4F 31.8 ng/l, p < 0.005), and healthy age-matched controls (112.8F 53.4 ng/l, p < 0.001;
Bonferroni corrected two-tailed Student’s t-test). There was no difference of S100B between unmedicated patients and controls
( p>0.05). Patients with deficit (250.6F 154.9 ng/l) had higher S100B levels than patients with nondeficit schizophrenia
(146.7F 107.2 ng/l, p < 0.05) or controls ( p < 0.005). S100B was positively correlated with the subscore ‘thought disturbance’
of the Brief Psychiatric Rating Scale ( p < 0.05). In summary, increased serum levels of S100B may indicate alterations of
astrocytes during early treatment with antipsychotics and in deficit schizophrenia. Whether S100B is elevated due to injured
astrocytes and a disrupted blood–brain barrier, or by active secretion of S100B by astrocytes, has to be clarified by further
studies.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
S100 proteins are a family of acidic proteins that
can bind calcium and thus influence several cellular
responses along the calcium-signal-transduction path-
way (Scha¨fer and Heizmann, 1996). The monomer
S100B is found in the central nervous system, espe-
cially in the cytoplasm of astrocytes. It can form
homo- or heterodimers with S100A1. Each monomer
has a molecular weight of approximately 10 kDa.
S100B regulates cell shape, energy metabolism, con-
traction, cell-to-cell communication, intracellular sig-
nal transduction, cell growth (Zimmer et al., 1995),
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and can be released by astrocytes (Pinto et al., 2000).
Interestingly, the effects of extracellular S100B
depend on its concentration (Scha¨fer and Heizmann,
1996). Nanomolar concentrations act as growth and/or
differentiation factor for neurons and astrocytes,
whereas micromolar concentrations may induce apop-
tosis, for instance in pheochromocytoma cells. Serum
concentration of S100B has been used as a marker for
structural damage to the brain, particularly to astro-
cytes, for instance after cardiopulmonary bypass sur-
gery (Abdul-Khaliq et al., 1999, 2000).
It is known that serum levels of S100B are elevated
in untreated patients with schizophrenia in compar-
ison with healthy controls (Lara et al., 2001; Roth-
ermundt et al., 2001). However, the impact of
antipsychotic medication on S100B is controversial.
Increased (Wiesmann et al., 1999) and decreased
levels (Gattaz et al., 2000) of S100B were reported
in medicated schizophrenic patients in comparison
with healthy controls. Further, Rothermundt et al.
(2001) showed that treatment with antipsychotics for
6 weeks reduced S100B in this subgroup of patients,
which had less negative symptoms, whereas S100B
was unchanged in the subgroup with more negative
symptoms at admission and after 6 weeks treatment.
Therefore, we investigated the impact of medication
on serum levels of S100B in a larger sample of
schizophrenic patients. Negative symptoms that occur
especially in the deficit syndrome influence S100B
(Kirkpatrick et al., 2001; Rothermundt et al., 2001).
Thus, the deficit syndrome was included as an addi-
tional factor in the analysis.
2. Methods
The patients consisted of 30 Caucasian subjects
with schizophrenia (16 female, 14 male; 16 medi-
cated, 14 drug-free), who were treated as inpatients in
the Department of Psychiatry of a University affiliated
hospital. Schizophrenia was diagnosed independently
by two psychiatrists according to the criteria of the
diagnostic and statistical manual of mental disorders
(DSM-IV; American Psychiatric Association, 1994)
and the international classification of diseases (ICD-
10; World Health Organization, 1993). The semistruc-
tured interview according to the AMDP-system
(Arbeitsgemeinschaft fu¨r Methodik und Dokumenta-
tion in der Psychiatrie) and ICD-10 checklists were
used for diagnosis (Haug and Stieglitz, 1997). Sys-
temic diseases (neoplasms, autoimmune diseases,
infectious diseases and cardiovascular and neurolog-
ical diseases) were ruled out by taking a detailed
history, reviewing charts, physical examination and
measuring the body temperature, C-reactive protein
and erythrocyte sedimentation rate. Further, subjects
were controlled for drug and alcohol abuse. Fifteen
healthy Caucasian subjects (seven female, eight male)
were recruited from the medical personnel as controls.
Disorders as mentioned above and psychiatric disor-
ders were excluded by taking a detailed history.
Controls did not take any drugs.
There was no statistically significant difference
between the mean age of patients (34.8F 12.4 years)
and controls (34.2F 5.6 years; two-tailed Student’s t-
test T= 0.22, p>0.05). Schizophrenia was character-
ized on average by a total lifetime duration of
8.9F 8.8 years and a number of 8.1F 7.6 episodes.
The mean age at onset of first episode was 25.3F 9.7
years. The severity of schizophrenic symptoms was
assessed with the Brief Psychiatric Rating Scale
(BPRS; Overall and Gorham, 1962; Collegium Inter-
nationale Psychiatriae Scalarum, 1996). The total
BPRS score was on average 45.3F 12.6. The deficit
syndrome was determined according to the criteria by
Kirkpatrick et al. (2001). Patients with schizophrenia
were treated according to the guidelines of the Amer-
ican Psychiatric Association (1997) and the expert
consensus guidelines for the treatment of schizophre-
nia (McEvoy et al., 1999). Medicated schizophrenic
patients received typical (flupentixol, fluphenazine,
haloperidol, perazine, pimozide, zuclopenthixol;
N = 7), atypical (amisulpiride, clozapine, olanzapine,
risperidone, sulpiride; N = 4), or both kinds of anti-
psychotics (N = 5), on average 363.1F 248.8 mg
chlorpromazine equivalents/day (no difference bet-
ween groups; ANOVA df = 2, F = 3.7, p>0.05). Atyp-
ical drugs were administered, when typical agents led
to severe extrapyramidal symptoms, when symptoms
did not respond to typical drugs and when a high
amount of negative symptoms was present. Patients
treated with atypical agents alone did not receive
typical ones before. Patients were treated on an
average of 20.9F 24 days (N = 14) before the deter-
mination of S100B; only two patients were medicated
for more than 8 months before S100B was determined
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(no difference between medication groups; df = 2,
F = 0.93, p>0.05). The investigation was carried out
in accordance with the latest version of the Declara-
tion of Helsinki. After complete description of the
study to the subjects, a written informed consent was
obtained. The research protocol was approved by the
local ethics committee.
Blood samples were obtained by venipuncture
performed at 8 a.m. Within 2 h, the serum samples
were centrifuged (2 jC, 3500 rpm, 10 min), and
stored at  70 jC until analysis. Serum concentra-
tions of S100B were determined with a monoclonal
two-site immunoluminometric assay (LIA-mat Byk-
Sangtec-100, AB Sangtec Medical, Bromma, Sweden;
sandwich principle). The detection limit of the assay
was 100 ng/l. Values below 100 ng/l were reported as
99 ng/l. Data are reported as meanF S.D. Serum
concentrations of S100B were analyzed with an
ANOVA, including medication, and deficit vs. non-
deficit syndrome as main factors. Thereafter, groups
were compared post hoc with two-tailed Student’s t-
test. Significance values were adjusted for multiple
comparisons according to Bonferroni. Concerning
medication, the respective treatment 3 days before
the determination of S100B was considered, assuming
a delay of the medication effect. A stepwise multiple
regression analysis was performed to analyze whether
S100B was related to the severity of schizophrenia,
age, total lifetime duration of the disorder, the number
of episodes and age at onset of first episode.
3. Results
The ANOVA revealedmedication (df = 1,F = 11.68,
p< 0.005) and deficit vs. nondeficit syndrome (df = 2,
F = 5.09, p < 0.05) as factors that influenced serum
concentrations of S100B significantly. There was no
significant interaction between these factors (df = 2,
F = 2.4, p>0.05). To further assess the impact of
medication (Fig. 1), unmedicated, medicated patients
and healthy controls were compared post hoc with
Student’s t-tests. S100B was significantly higher in
schizophrenic patients treated with antipsychotic
drugs (241.1F152.5 ng/l, N = 16) than in unmedi-
cated patients (111.4F 31.8 ng/l, N = 14; p < 0.005)
and healthy controls (112.8F 53.4 ng/l, N = 15;
p< 0.001). However, there was no statistically signi-
ficant difference between untreated patients and con-
trols ( p>0.05).
The ANOVA revealed a significant effect of the
deficit syndrome on serum concentrations of S100B.
As illustrated in Fig. 2, patients with deficit schizo-
phrenia (250.6F 154.9 ng/l, N = 12) had significantly
Fig. 1. Serum concentrations of S100B in 15 healthy controls
(Control; 112.8F 53.4 ng/l), 14 unmedicated schizophrenic patients
(w/o; 111.4F 31.8 ng/l) and 16 schizophrenic patients treated with
antipsychotic drugs (AP; 241.1F152.5 ng/l). Significance values
were calculated by Bonferroni corrected two-tailed Student’s t-test.
Fig. 2. Serum concentrations of S100B in 15 healthy controls
(112.8F 53.4 ng/l), 11 patients with nondeficit schizophrenia
(146.7F 107.2 ng/l) and 12 patients with deficit schizophrenia
(250.6F 154.9 ng/l). Significance values were calculated by
Bonferroni corrected two-tailed Student’s t-test.
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higher S100B levels than patients with the nondeficit
form of the disease (146.7F 107.2 ng/l, N = 11) and
healthy controls ( p < 0.05, < 0.005, respectively; Stu-
dent’s t-test). There was no significant difference
between S100B concentration in nondeficit schizo-
phrenia and healthy controls ( p>0.05). Patients suffer-
ing from schizophrenia with an uncertain course
(113.6F 30.3 ng/l, N = 7) were excluded from this
comparison because illness duration was less than 1
year.
The multiple regression analysis demonstrated that
S100B was related to the severity of schizophrenia
(total BPRS score), whereas there was no effect of
age, total lifetime duration of the disorder, the num-
ber of episodes and age at onset of first episode
(Table 1). The regression analysis isolated the third
BPRS subscore (thought disturbance) as the specific
subscore that influenced serum concentrations of
S100B significantly. The correlation between S100B
and the third BPRS subscore remained also statisti-
cally significant when it was controlled for medication
and deficit syndrome (two-tailed partial correlation
r= 0.42, p < 0.05).
4. Discussion
Our results demonstrate that serum concentrations
of S100B are higher in schizophrenic patients treated
with antipsychotics when compared with unmedicated
patients and healthy controls. Thus, the data suggest
that antipsychotics increase serum concentrations of
S100B. Astrocytes may actively secrete S100B (Pinto
et al., 2000) and possess D2 receptors, at least in
specific brain regions (Khan et al., 2001). Because
particularly typical antipsychotics act via D2 receptors
(Kapur and Seeman, 2001), they may trigger eleva-
tions of the intracellular messenger cyclic adenosine
3V,5V-monophosphate (cAMP) (Siegel et al., 1999).
Astrocytes in turn may secrete S100B, induced for
instance by the cAMP regulatory element (Zimmer et
al., 1995; Pinto et al., 2000). This hypothesis may
explain the higher serum levels of S100B in medi-
cated patients in comparison with unmedicated
patients and healthy controls in our study, particularly
because the majority of patients received typical
antipsychotics. Thus, our results are in accordance
with Wiesmann et al. (1999) who showed elevated
S100B levels in medicated schizophrenic patients
compared with healthy controls.
On the other hand, our results are inconsistent with
reports by Gattaz et al. (2000), which demonstrated
reduced plasma levels of S100B in (mostly with
clozapine) medicated schizophrenic patients com-
pared with healthy controls. This difference might
be explained by a different duration of antipsychotic
treatment before the measurement of S100B in the
studies. In our study, almost all patients were treated
on an average of 3 weeks before the determination of
S100B. Rothermundt et al. (2001) showed that treat-
ment with antipsychotics for 6 weeks reduced S100B
in this subgroup of patients, which had less negative
symptoms, whereas S100B was unchanged in the
subgroup with more negative symptoms at admission
and after 6 weeks treatment. Thus, one may hypothe-
size that antipsychotics increase S100B during the
first weeks of treatment, whereas in the long run, after
more than 5 weeks, they decrease S100B, at least in
patients with a small amount of negative symptoms.
According to this hypothesis, Wiesmann et al. (1999)
and our study measured elevated S100B during the
first weeks of treatment, whereas Gattaz et al. (2000)
and Rothermundt et al. (2001) measured decreased
levels of S100B after more than 5 weeks of treatment,
at least in patient subgroups.
Moreover, we demonstrate higher S100B levels in
deficit than nondeficit schizophrenia, which corre-
sponds to Rothermundt et al. (2001), reporting a
correlation between S100B and negative symptoma-
tology. The data may suggest that S100B serum levels
are related to the deficit syndrome in schizophrenia,
Table 1




Total lifetime duration of disorder 0.203 n.s.
Number of episodes 0.325 n.s.
Age at onset of first episode  0.109 n.s.
Total BPRS score 0.391 < 0.05
BPRS 1: anxiety/depression 0.179 n.s.
BPRS 2: anergia 0.118 n.s.
BPRS 3: thought disturbance 0.363 < 0.05
BPRS 4: activation 0.17 n.s.
BPRS 5: hostile-suspiciousness 0.061 n.s.
BPRS: Brief Psychiatric Rating Scale.
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which was proposed to be a separate disease within
the schizophrenic syndrome (Kirkpatrick et al., 2001).
Further, we show a positive correlation between
S100B and the severity of thought disturbance in
schizophrenia, which was also found in depression
with psychotic features (Schroeter et al., in press).
Lara et al. (2001) and Rothermundt et al. (2001)
reported higher serum levels of S100B in untreated
patients with schizophrenia in comparison with
healthy controls. On the contrary, we did not find
such differences, presumably due to a higher detection
limit in our study.
One might suppose that the three factors (medica-
tion, deficit syndrome and third BPRS subscore) that
had an impact on serum levels of S100B in our study
might be interrelated. Then, differences concerning
medication might just be caused by differences in the
deficit syndrome between medicated and unmedicated
patients. However, the ANOVA revealed no interac-
tion between the main factors medication and deficit
syndrome. Further, the correlation between S100B
and the third BPRS subscore remained significant
after controlling for medication and deficit syndrome.
Thus, medication, deficit syndrome and the third
BPRS subscore seem to be independent factors influ-
encing serum levels of S100B in schizophrenia.
Summarizing the data, increased serum levels of
S100B may indicate alterations of astrocytes (Scha¨fer
and Heizmann, 1996) in the deficit syndrome of
schizophrenia, and during early treatment with anti-
psychotics. Whether S100B serum levels are elevated
due to damage to the brain, particularly astrocytes
(Abdul-Khaliq et al., 1999, 2000), and a subsequent
disruption of the astrocytically supported blood–brain
barrier (Schroeter et al., 1999, 2001), or by the active
secretion of S100B by astrocytes (Pinto et al., 2000),
has to be clarified by further studies.
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